At present, Biogen Canada’s focus is in the therapeutic areas of Multiple Sclerosis and Hemophilia. Biogen strives to be a pioneer in the research and development of advanced therapies for these disease areas.
Biogen Canada currently has four Multiple Sclerosis therapies on the market, and one therapy each for Hemophilia A and Hemophilia B.
Links to comprehensive information about our products are listed below, in the form of a document known as a product monograph. This information has been approved by Health Canada and should be read and discussed in consultation with a health care professional.